Pan-cancer analysis of <i>ARID1A</i> Alterations as Biomarkers for Immunotherapy Outcomes
Tao Jiang(Chongqing University), Caicun Zhou(Tongji University), Shengxiang Ren(Tongji University), Chunxia Su(Tongji University), Xiaoxia Chen(Shanghai Pulmonary Hospital)
Cited by 142
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504